A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Launched by PFIZER · Mar 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called Tafamidis, which is being tested for its effects on a heart condition known as Transthyretin Amyloid Cardiomyopathy (ATTR-CM). The trial aims to understand how well Tafamidis works and whether it is safe for people who have been diagnosed with this condition. To be eligible for the study, participants need to be at least 19 years old, have been diagnosed with ATTR-CM, and must have already received a prescription for Tafamidis and taken it at least once.

Those who join the trial can expect to share their experiences while taking Tafamidis, which will help researchers learn more about the medicine. It’s important to note that individuals with other types of amyloidosis are not eligible to participate in this study. The trial is currently active but not recruiting new participants, meaning they are not looking for additional volunteers at this time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥19 years
• • Patients diagnosed with ATTR-CM (ATTRwt and ATTRv) with tissue biopsy or nuclear scintigraphy
• • Patients who was prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once.
• Exclusion Criteria:
• • Presence of other amyloidosis